🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

Recruitingn/aAges 18 Years - anyAllFederation Francophone de Cancerologie Digestive
NCT06541652 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 18 years of age or older, * with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma * diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort * for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies. Exclusion Criteria: * without social security * No access to tumor block
💊

What it tests

  • Not listed
📍

Where

40 sites
CHU Amiens picardie
Amiens, France
Chu Angers
Angers, France
Ch - Centresimone Veil de Beauvais
Beauvais, France
Chu Jean Minjoz
Besançon, France
Ch Bethune Beuvry
Béthune, France
Avicenne
Bobigny, France
Cote de Nacre
Caen, France
Centre Hospitalier
Calais, France

…and 32 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy